Published in Drug Week, April 1st, 2005
"Antibodies directed against AbetaP have been suggested to be effective in the treatment of Alzheimer disease (AD). Here, we used in vivo and in vitro models to test some of the mechanisms by which antibodies may produce their effects," wrote W.A. Banks and colleagues, Veterans Affairs Medical Center.
"We found that the blood-to-brain uptake of murine AbetaP1-42 was significantly reduced when co-injected peripherally with an antibody known to reverse cognitive defects in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.